Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study
Main finding · Any cancer (except non-melanoma skin cancer)Result — go to the resultHazard ratio 1.41 95% CI 0.76–2.37Authors' conclusion
JAKi treatment in real-world patients with RA was not associated with a statistically significant increased risk of first primary cancer compared with those who received bDMARDs.
Study context
- Population
- Patients with RA aged 18+ years without previous cancer who initiated janus kinase inhibitors (JAKi) or bDMARDs, 1 January 2017 to 31 December 2020, Denmark
- Participants
- 875 vs 4,247
- Exposure
- JAKi vs bDMARDs
- JAKin = 875
- bDMARDn = 4,247reference
- Outcome
- First primary cancer (any cancer except non-melanoma skin cancer)
Methodological detailsobservational, inverse probability of treatment weighting (IPTW), cause-specific Cox models
- Observational
- Inverse probability of treatment weighting (IPTW)
- Cause-specific Cox models
Main finding
Any cancer (except non-melanoma skin cancer)
Hazard ratio
1.41
95% CI 0.76–2.37
Events by group
JAKivs bDMARD
HR 1.41 (95% CI 0.76–2.37)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford). Published 13 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →